Cardiomegaly and vasoactive hormones in rats with chronic myocardial infarction: Long-term effects of chlorothiazide

Clinical Science

Volumn 90, Issue 1, 1996, Pages 31-36

  Kohzuki, Masahiro ^a   Kanazawa, Masayuki ^b   Yoshida, Kazunori ^b   Tsutsumi, Eikatsu ^b   Yasujima, Minoru ^c   Abe, Keishi ^c   Johnston, Colin I ^d   Sato, Tokutaro ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Second Dept of Internal Medicine   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atrial natriuretic peptide; Diuretics; Heart failure; Renin; Total exchangeable body sodium

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CHLOROTHIAZIDE; RENIN; SODIUM ION; VASOACTIVE AGENT; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMEGALY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; FEMALE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMATOCRIT; HORMONE BLOOD LEVEL; LEFT CORONARY ARTERY; LUNG CONGESTION; LUNG WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA OSMOLALITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; VASOPRESSIN BLOOD LEVEL;

EID: 0030069587     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0900031     Document Type: Article

References (41)

1. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406-12.
2. Packer M, Lee WH, Yashak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315: 847-53.
3. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Consensus Study. N Engl J Med 1987; 316: 1429-34.
4. Sweet CS, Emmert SE, Stabilito II, Ribeiro LGT. Increased survival in rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol 1987; 10; 636-42.
5. Michel JB, Lattion AL, Salzmann JL, et al. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res 1988; 62: 641-50.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1991; 325: 293-302.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1992; 327: 685-91.
8. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 1993; 11 (Suppl. 4): 61-73.
9. Hodsman GP, Sumithran E, Harrison RW, Johnston CI. Cardiac hypertrophy and salt status in chronic myocardial infarction in the rat: effects of enalapril versus salt restriction. J Cardiovasc Pharmacol 1988; 12: 467-72.
10. Kitamura S, Kay JH, Krohn BG, Maadigson O, Dunn EF. Geometric and functional abnormalities of the left ventricle with a chronic localized noncontractile area. Am J Cardiol 1973; 31: 701-7.
11. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979; 44: 503-12.
12. Selye H, Bajusz E, Grasso S, Mendell P. Simple techniques for the surgical occlusion of the coronary vessels in the rat. Angiology 1960; 11: 398-407.
13. Dusting GJ, Harris GS, Rand MJ. A specific increase in cardiovascular reactivity related to sodium retention in DOCA-salt treated rats. Clin Sci Mol Med 1973; 45: 571-81.
14. McAreavay D, Shackleton DR, Brown WB, East BW, Robertson JIS. The management of exchangeable sodium and total body sodium in rats in vivo compared with chemical analysis post-mortem. J Lab Clin Med 1983; 102: 140-6.
15. Woods RL, Johnston CI. Contribution of vasopressin to the maintenance of blood pressure during dehydration. Am J Physiol 1983; 245: F615-21.
16. Johnston CI, Millar JA, Casley DJ, MacGrath BP, Matthews PG. Hormonal response to angiotensin blockade: comparison between receptor angiotensin and angiotensin converting enzyme inhibition. Circ Res 1980, 46 (Suppl. 1): 128-34.
17. Ogawa K, Smith AI, Hodsman GP, Jackson B, Woodcock EA, Johnston CI, Plasma atrial natriuretic peptide: concentrations and circulating forms in normal man and patients with chronic renal failure. Clin Exp Pharmacol Physiol 1987; 14: 95-102.
18. Pfeffer MA, Pfeffer JM. Pharmacologic regression of cardiac hypertrophy in experimental hypertension. J Cardiovasc Pharmacol 1984; 6 (Suppl. 6): 865-9.
19. Tarazi RC, Fouad FM. Reversal of cardiac hypertrophy by medical treatment. Ann Rev Med 1985; 36: 407-14.
20. Tarazi RC, Sen S, Fouad FM, Wicker R. Regression of myocardial hypertrophy: conditions and sequelae of reversal in hypertensive heart disease. In: Alpert NR, et al. Perspectives in cardiovascular research. Vol 7. Myocardial hypertrophy and failure. New York: Raven Press, 1983: 637-52.
21. Sen S, Tarazi RC, Khairallah PA, Bumpus FMM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35: 775-81.
22. Frohlich ED, Tarazi RC. Is arterial pressure the sole factor for hypertensive cardiac hypertrophy? Am J Cardiol 1979; 44: 959-63.
23. Harlan WR, Oberman A, Grimm R, Rosati RA. Chronic congestive heart failure in coronary artery disease: clinical criteria. Ann Intern Med 1977; 86: 133-8.
24. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RD, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-31.
25. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to progress in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
26. Singer DRJ, Shore AC, Markandu ND, Buckley MG, MacGregor GA. Atrial natriuretic peptide levels in treated congestive heart failure. Lancet 1986; i: 851.
27. Hodsman GP, Kohzuki M, Howes LG, Smithran E, Tsunoda K, Johnston CI. Neurohumoral responses to chronic myocardial infarction in rats. Circulation 1988; 78: 376-81.
28. Manhem PJO, Clark SA, Brown WB, Murray GD, Robertson JIS. Effect of chlorothiazide on serial measurements of exchangeable sodium and blood pressure in spontaneously hypertensive rats. Clin Sci 1985; 69: 511-15.
29. Tsunoda K, Hodsman GP, Sumithran E, Johnston CI. Atrial natriuretic peptide in chronic heart failure in the rat: a correlation with ventricular dysfunction. Circ Res 1986; 59: 256-61.
30. Hodsman GP, Harrison RW, Sumithran E, Johnston CI. Atrial natriuretic peptide and total exchangeable body sodium: relationships in rats with chronic myocardial infarction. Clin Sci 1988; 74: 659-63.
31. Kohzuki M, Hodsman GP, Johnston CI. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol 1989; 256: H533-8.
32. Kohzuki M, Hodsman GP, Harrison RW, Patrick W, Johnston CI. Attenuated renal and hypotensive responses to atrial natriuretic peptide infusion and changes in cyclic GMP in rats with heart failure. J Cardiovasc Pharmacol 1989; 13 (Suppl. 6): 43-6.
33. Khairallah PA, Kanabus J. Angiotensin and myocardial protein synthesis. In: Tarazi RC, Dunbar JB, eds. Left ventricular hypertrophy in hypertension. New York: Raven Press, 1983: 337-48.
34. Richard NE. Cellular mechanisms of growth in cardiovascular tissue. Am J Cardiol 1987; 60: 104-91.
35. Frohlich ED. Potential mechanisms explaining the risk of left ventricular hypertrophy. Am J Cardiol 1987; 59: 91-7A.
36. Alderman EL, Harrison DC, Myocardial hypertrophy resulting from low dosage isoproterenol administration in rats. Proc Soc Exp Biol Med 1971; 136: 268-70.
37. Howes LG, Hodsman GP, Rowe PR, Sumithran E, Johnston CI. Cardiac 3,4 dihydroxyphenylethylene glycol (DHPG) and catecholamine levels during perindopril therapy of chronic left ventricular failure in rats. J Autonom Pharmacol 1988; 8: 355-62.
38. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and heart failure. Arch Intern Med 1993; 153: 939-42.
39. Johnston CI. Franz Volhard Lecture, Renin angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992; 10 (Suppl. 7): 13-26.
40. MacFadyen RJ. Role of the circulating and tissue-based renin-angiotensin system in the development of heart failure. Cardiology 1993; 83: 38-48.
41. Kohzuki M, Johnston CI. Inhibition of angiotensin converting enzyme in various organs. Ther Res 1989; 10: 32-8.